Biotechnology News and Research RSS Feed - Biotechnology News and Research

Changing breast cancer cells' shape could make the disease more sensitive to treatments

Changing breast cancer cells' shape could make the disease more sensitive to treatments

Changing the shape of breast cancer cells could make the disease more sensitive to treatments - even driving the body's own inflammatory response against a tumour - a new study shows. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
Common antidepressant medications not helpful for people with mood, anxiety disorders

Common antidepressant medications not helpful for people with mood, anxiety disorders

Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood. [More]
Regenicin receives final payment to conclude Asset Purchase Agreement with Amarantus

Regenicin receives final payment to conclude Asset Purchase Agreement with Amarantus

Regenicin, Inc. a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has received the final payment to conclude The Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. [More]
VWR, New England Biolabs expand distribution agreement

VWR, New England Biolabs expand distribution agreement

VWR, a leading, independent provider of laboratory products, services and solutions, announced today the expansion of its distribution agreement with New England Biolabs, Inc. [More]
FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers. [More]
Experts review diagnostic approaches to treat obstructive coronary artery disease in women

Experts review diagnostic approaches to treat obstructive coronary artery disease in women

Obstructive coronary artery disease (CAD) in women often presents with different types of symptoms than in men and can be challenging to diagnose due to a variety of factors. A national panel of experts convened to review the latest evidence regarding CAD in women, diagnostic approaches, and new types of tests and technologies. [More]

BioMed Realty recaptures valuable properties in Cambridge innovation district

BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015. [More]
Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube. [More]
Modified measles vaccine effective against Chikungunya virus, study finds

Modified measles vaccine effective against Chikungunya virus, study finds

A modified, conventional measles vaccine has the potential to act against the Chikungunya virus. This is the result of a study at the University Clinic for Clinical Pharmacology of the MedUni Wien (Medical University of Vienna), which has now been published in the top journal "The Lancet Infectious Diseases". [More]
WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). [More]
New strategy may ensure safety of adult epidermal stem cells before performing treatments

New strategy may ensure safety of adult epidermal stem cells before performing treatments

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria. [More]
Intrexon signs agreement to acquire Okanagan Specialty Fruits

Intrexon signs agreement to acquire Okanagan Specialty Fruits

Intrexon Corporation, a leader in synthetic biology, today announced it has entered into an agreement to acquire Okanagan Specialty Fruits, the pioneering agricultural company behind the Arctic apple, the world's first non-browning apple. [More]

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference. [More]
Single-step fermentative method may facilitate industrial-scale statin drug production

Single-step fermentative method may facilitate industrial-scale statin drug production

University of Manchester researchers, together with industrial partner DSM, have developed a single-step fermentative method for the production of leading cholesterol-lowering drug, pravastatin, which will facilitate industrial-scale statin drug production. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Study: Plant compounds can help prevent liver damage during menopause

Study: Plant compounds can help prevent liver damage during menopause

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease. [More]
Researchers develop revolutionary approach to treat drug-resistant tumors

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. [More]
Garlic compound can help fight lung infections in people with cystic fibrosis

Garlic compound can help fight lung infections in people with cystic fibrosis

A chemical found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests. [More]

Berthold Technologies introduces Biametrics GmbH as a new co-operation partner

Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH. [More]